stockrowAstraZeneca PLC (AZN) vs Gilead Sciences, Inc. (GILD)
- AstraZeneca PLC AZN 187.20 −0.96%
- Gilead Sciences, Inc. GILD 167.46 −4.02%
AstraZeneca PLC and Gilead Sciences, Inc. are both Drug Manufacturers General companies. AstraZeneca PLC is the larger, with a market value of $289.8B against $207.8B — 1.4× the size. Gilead Sciences, Inc. has negative trailing earnings, so its P/E is not meaningful; AstraZeneca PLC trades at 26.3×. AstraZeneca PLC grew revenue faster over the last twelve months: 7.32% against 6.54%. AstraZeneca PLC has the higher net margin (17.7% vs −12.5%) and the higher return on invested capital (12.3% vs −4.51%). Both pay a dividend; Gilead Sciences, Inc. yields more (1.94% vs 1.71%). Across the 22 metrics below, AstraZeneca PLC leads on 15 and Gilead Sciences, Inc. on 7.
Valuation
Profitability
| Metric | AZN | GILD | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.94% | 79.93% | 73.01% |
| Operating margin | 23.68% | (7.63%) | 18.34% |
| Net margin | 17.68% | (12.47%) | 7.31% |
| Free cash flow margin | 10.15% | 44.47% | 18.52% |
| Return on equity | 22.56% | (22.45%) | 5.80% |
| Return on assets | 9.41% | (7.03%) | 2.28% |
| Return on invested capital | 12.31% | (4.51%) | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack